In a reversal of its past position, a majority of a 26-person Food and Drug Administration advisory panel voted to recommend looser restrictions on the controversial diabetes drug Avandia.
You are receiving this email because you subscribed to this feed at blogtrottr.com.
No comments:
Post a Comment